Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients.

Nicola GianottiAndrea PoliSilvia NozzaLaura GalliNadia GalizziMarco RipaMarco MerliAlessia CarboneVincenzo SpagnuoloAdriano LazzarinAntonella Castagna

Published in: BMC infectious diseases (2017)

In our clinical practice, the durability of the two regimens was comparable and both showed a very low probability of VF.

Keyphrases

hiv infected
antiretroviral therapy
clinical practice
end stage renal disease
hiv infected patients
newly diagnosed
ejection fraction
peritoneal dialysis
prognostic factors
human immunodeficiency virus
hepatitis c virus